Thursday, January 07, 2021 5:37:42 PM
Add to that the UCLA Medical School is behind the DCVax-L.
Look at the following quotes during the talks by Dr. Linda Liau and Dr. Leia Nghiemphu.
Dr. Linda Liau (Fellow of National Academy of Medicine) talking about the DCVax-L therapy at the UAB on November 6th, 2020: "It is good for the patients."
Dr. Leia Nghiemphu of the UCLA School of Medicine on December 4th, 2020 at the UCLA Brain Tumor Virtual Conference: "There are several vaccines out there. Here at UCLA, we use the dendritic cell vaccine."
UCLA is a top medical school and I don't think they will be using DCVax-L unless they think that it is efficacious.
Look at the following quotes during the talks by Dr. Linda Liau and Dr. Leia Nghiemphu.
Dr. Linda Liau (Fellow of National Academy of Medicine) talking about the DCVax-L therapy at the UAB on November 6th, 2020: "It is good for the patients."
Dr. Leia Nghiemphu of the UCLA School of Medicine on December 4th, 2020 at the UCLA Brain Tumor Virtual Conference: "There are several vaccines out there. Here at UCLA, we use the dendritic cell vaccine."
UCLA is a top medical school and I don't think they will be using DCVax-L unless they think that it is efficacious.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
